Terns Pharmaceuticals, Inc. (TERN)

US — Healthcare Sector

Peers: AMLX ABOS INZY XFOR MREO PDSB HOOK DAWN ELDN

Automate Your Wheel Strategy on TERN

With Tiblio's Option Bot, you can configure your own wheel strategy including TERN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

symbol TERN
Rev/Share 0.0
Book/Share 3.5643
PB 0.8697
Debt/Equity 0.0038
CurrentRatio 30.8869
ROIC -0.3161

MktCap 270747180.0
FreeCF/Share -0.7835
PFCF -3.7776
PE -3.1372
Debt/Assets 0.0036
DivYield 0
ROE -0.2881

Rating B-
Score 3
Recommendation Neutral
P/E Score 1
DCF Score 4
P/B Score 4
D/E Score 4

Recent Analyst Ratings

Type	Ticker	Analyst Firm	Previous Rating	Current Rating	Previous Price Target	Current Price Target	Date
Initiation	TERN	William Blair	--	Market Perform	--	--	Feb. 28, 2025

News

Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701

TERN
Published: May 14, 2025 by: GlobeNewsWire
Sentiment: Neutral

Preclinical data highlight improved potency vs. asciminib across multiple clinically relevant variants of BCR-ABL including difficult-to-treat resistance mutations

image for news Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701

Down -39.83% in 4 Weeks, Here's Why Terns Pharmaceuticals (TERN) Looks Ripe for a Turnaround

TERN
Published: April 07, 2025 by: Zacks Investment Research
Sentiment: Positive

Terns Pharmaceuticals (TERN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

image for news Down -39.83% in 4 Weeks, Here's Why Terns Pharmaceuticals (TERN) Looks Ripe for a Turnaround

All You Need to Know About Terns Pharmaceuticals (TERN) Rating Upgrade to Buy

TERN
Published: March 26, 2025 by: Zacks Investment Research
Sentiment: Positive

Terns Pharmaceuticals (TERN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

image for news All You Need to Know About Terns Pharmaceuticals (TERN) Rating Upgrade to Buy

About Terns Pharmaceuticals, Inc. (TERN)

IPO Date 2021-02-05
Website https://www.ternspharma.com
Industry Biotechnology
CEO Ms. Amy L. Burroughs M.B.A.
Employees 59

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.